Trials / Unknown
UnknownNCT04182568
Nab-paclitaxel Compared With Docetaxel Followed by Anthracyclines and Cyclophosphamide in the Neoadjuvant Breast Cancer
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Xijing Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open, multicenter, randomized controlled clinical trial for patients with newly diagnosed primary invasive breast cancer and clinical stage of T2 or above. The main purpose of this study is to evaluate the efficacy of dose-dense nab-paclitaxel compared with dose-dense docetaxel followed by anthracycline and cyclophosphamide in the treatment of HR positive and HER-2 negative breast cancer. The effectiveness and safety of the treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | nab-paclitaxel followed by anthracycline and cyclophosphamide | nab-paclitaxel 260mg/m2 for every 2 weeks followed by anthracycline and cyclophosphamide |
| DRUG | Docetaxel followed by anthracycline and cyclophosphamide | Docetaxel 100 mg/m2 for for every 2 weeks followed by anthracycline and cyclophosphamide |
Timeline
- Start date
- 2019-08-21
- Primary completion
- 2021-08-21
- Completion
- 2022-08-21
- First posted
- 2019-12-02
- Last updated
- 2019-12-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04182568. Inclusion in this directory is not an endorsement.